Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options

E-ISSN： 1875-6301|11|4|269-291

ISSN： 1573-3947

Source： Current Cancer Therapy Reviews, Vol.11, Iss.4, 2015-12, pp. : 269-291

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia Pronzato Paolo Del Mastro Lucia

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos Esteva Francisco

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

HER2-Positive Breast Cancer: Incidence, Prognosis, and Treatment Options

By Estévez L.G.

American Journal of Cancer, Vol. 2, Iss. 3, 2003-01 ,pp. : 169-179

Adis International

Access to resources Recommend Favorite

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

By Eiermann W.

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

By Zagouri Flora

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 13-22

Springer Publishing Company

Access to resources Recommend Favorite